Xarelto Lawsuit Plaintiffs See Consolidation Of Philadelphia, Pennsylvania Mass Tort Program

April 07, 2016 – – BloodThinnerHelp.com reports on the continued growth of Xarelto lawsuit numbers which were consolidated to form a mass tort program by the Court of Common Pleas in Philadelphia, Pennsylvania. The involved complaints were unanimously filed against defendants Bayer AG and Johnson & Johnson subsidiary Janssen Pharmaceutical. The plaintiffs filing share strikingly similar claims that the anticoagulant drug Xarelto places patients taking it at heightened risk for the development of sudden, dangerous bleeding episodes which sometimes prove fatal.

At this time, it has been reported that the mass tort program includes more than 620 cases, and is joined by another 2,800 Xarelto lawsuits which were consolidated in a single court in Eastern Louisiana to form MDL number 2592 by the U.S. Judicial Panel on Multidistrict Litigation. Together, these groupings make up more than 3,400 lawsuits filed against Xarelto manufacturers and expressing similar concerns.

Xarelto was released to the market in 2011 after gaining approval by the U.S. Food and Drug Administration. The FDA, however, has also given Xarelto two “black box” warnings, which are the most severe warnings a product can receive from the agency before being completely pulled from the market. For several years after the product’s initial launch, Xarelto was released without any corresponding antidote, which is another major point of contention among plaintiffs. This meant that if a patient became injured and bled, physicians were unable to easily counteract the effects of the medicine and get the blood to clot. This situation can make even minor bleeds incredibly dangerous.

Traditional blood thinners were instead released to the market with a corresponding antidote in vitamin K. This means that even from the start, if someone using a traditional blood thinner became injured and bled, physicians had the option of treating them with vitamin K which would counteract the blood thinner’s effects and clot their blood.

Today, lawsuits consolidated in both Pennsylvania and Louisiana continue to increase in number as they prepare for early 2017 bellwether trials. As time moves on, Attorney Joseph Osborne is working to help others who have used Xarelto and feel that it caused them health problems. Those affected could be entitled to significant compensation, and deserve the opportunity to fully evaluate their legal rights in the matter. To better ensure that this is possible for everyone deserving, Attorney Osborne is currently offering free legal consultations to qualified parties.

To ask questions regarding Xarelto lawsuits, or to request additional information, please contact Joseph Osborne, Esq. by calling (866) 425-8902.

###

Contact BloodThinnerHelp.com:

Joseph Osborne
866-425-8902
Mizner Park
433 Plaza Real Blvd., Ste. 271
Boca Raton, FL 33432

ReleaseID: 60009166